Paper Details

  1. Home
  2. Paper Details

Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

Author: EmeryV C, FeinbergJ E, GriffithsP D, GrywaczM, KnightS, SabinC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elevated CMV load in blood and urine at baseline was associated with increased risk of HCMV disease and a shorter survival time. Valacyclovir significantly suppressed the virus load in subjects who were PCR positive at baseline.
Paper Details　
Original Abstract of the Article :
Virus load is a major risk factor for disease in many human viral infections, especially human immunodeficiency virus (HIV) disease. The effect of cytomegalovirus (CMV) load on disease progression and the influence of antiviral chemotherapy on surrogate markers of replication was investigated in 310...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1086/314936

データ提供：米国国立医学図書館（NLM）

Valacyclovir and Cytomegalovirus: A Tale of Virus Load

The field of [virology] is a constant battle against viruses, like a camel facing a sandstorm. This research explores the relationship between cytomegalovirus (CMV) load, a measure of viral activity, and disease progression in people with advanced HIV disease. The researchers conducted a randomized controlled trial comparing the effects of valacyclovir and acyclovir on CMV replication. They found that higher CMV load in both blood and urine was associated with increased risk of CMV disease and shorter survival time. Valacyclovir was shown to be more effective than acyclovir in suppressing CMV load. This research highlights the importance of CMV load in predicting disease progression and the potential of valacyclovir to manage CMV infection in HIV-positive individuals.

The Impact of Virus Load

The study demonstrates that CMV load is a significant predictor of disease progression in patients with advanced HIV disease. The findings suggest that monitoring CMV load could be a valuable tool for predicting disease risk and guiding treatment decisions. Valacyclovir's effectiveness in suppressing CMV load could be beneficial in managing CMV infection and improving outcomes for HIV-positive individuals.

A Camel's Perspective on Viral Infections

As a camel, I'm well aware of the challenges of battling viruses in the desert. This research reminds me that knowing your enemy is key! Monitoring CMV load provides a vital tool for understanding the severity of infection and guiding treatment strategies. This research is a testament to the ongoing battle against viruses and the quest for effective therapies.

Dr. Camel's Conclusion

This study underscores the critical role of CMV load in predicting disease progression in HIV-positive individuals. Valacyclovir emerges as a potential therapeutic option for managing CMV infection in this patient population. Further research is needed to optimize the use of valacyclovir and other antiviral therapies for the treatment of CMV in individuals with HIV disease.

Date :
  1. Date Completed 1999-09-23
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

10438356

DOI: Digital Object Identifier

10.1086/314936

Related Literature

Article Analysis
・Effects of valacyclovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.